DE60033431D1 - Chimärische natriuretische peptide - Google Patents

Chimärische natriuretische peptide

Info

Publication number
DE60033431D1
DE60033431D1 DE60033431T DE60033431T DE60033431D1 DE 60033431 D1 DE60033431 D1 DE 60033431D1 DE 60033431 T DE60033431 T DE 60033431T DE 60033431 T DE60033431 T DE 60033431T DE 60033431 D1 DE60033431 D1 DE 60033431D1
Authority
DE
Germany
Prior art keywords
natriuretic peptides
chimeric natriuretic
peptides
chimeric
natriuretics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60033431T
Other languages
English (en)
Other versions
DE60033431T2 (de
Inventor
John Burnett
Ondrej Lisy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayo Foundation for Medical Education and Research
Original Assignee
Mayo Foundation for Medical Education and Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation for Medical Education and Research filed Critical Mayo Foundation for Medical Education and Research
Publication of DE60033431D1 publication Critical patent/DE60033431D1/de
Application granted granted Critical
Publication of DE60033431T2 publication Critical patent/DE60033431T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
DE60033431T 1999-12-17 2000-12-15 Chimärische natriuretische peptide Expired - Lifetime DE60033431T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US466268 1999-12-17
US09/466,268 US6407211B1 (en) 1999-12-17 1999-12-17 Chimeric natriuretic peptides
PCT/US2000/034080 WO2001044284A2 (en) 1999-12-17 2000-12-15 Chimeric natriuretic peptides

Publications (2)

Publication Number Publication Date
DE60033431D1 true DE60033431D1 (de) 2007-03-29
DE60033431T2 DE60033431T2 (de) 2007-11-29

Family

ID=23851133

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60033431T Expired - Lifetime DE60033431T2 (de) 1999-12-17 2000-12-15 Chimärische natriuretische peptide

Country Status (11)

Country Link
US (4) US6407211B1 (de)
EP (1) EP1242452B1 (de)
JP (1) JP5031964B2 (de)
AT (1) ATE353916T1 (de)
AU (1) AU2433901A (de)
CA (1) CA2395585C (de)
DE (1) DE60033431T2 (de)
DK (1) DK1242452T3 (de)
ES (1) ES2282160T3 (de)
PT (1) PT1242452E (de)
WO (1) WO2001044284A2 (de)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5043900A (en) * 1999-05-24 2000-12-12 Mayo Foundation For Medical Education And Research Adenovirus vectors encoding brain natriuretic peptide
US6407211B1 (en) * 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
US20050113286A1 (en) * 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
WO2003081246A1 (en) * 2002-03-18 2003-10-02 Scios Inc. Treatment of congestive heart failure with natriuretic peptide and a diuretic
US20080214437A1 (en) * 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
AU2003268531A1 (en) 2002-09-06 2004-03-29 University Of South Florida Materials and methods for treatment of allergic diseases
WO2004022579A2 (en) * 2002-09-06 2004-03-18 University Of South Florida Cellular delivery of natriuretic peptides
CA2504287A1 (en) 2002-11-26 2004-06-10 Nobex Corporation Natriuretic compounds, conjugates, and uses thereof
US20060177870A1 (en) * 2003-04-28 2006-08-10 Ciphergen Biosystems, Inc Immunoassays
ATE485303T1 (de) 2003-06-20 2010-11-15 Mayo Foundation Isoformen von gehirn-natriuretischem peptid
GB2403533A (en) * 2003-06-30 2005-01-05 Orion Corp Atrial natriuretic peptide and brain natriuretic peptide and assays and uses thereof
US7445933B2 (en) * 2003-07-16 2008-11-04 Abbott Laboratories, Inc. Stable calibrators or controls for measuring human natriuretic peptides
US7291501B2 (en) * 2003-07-16 2007-11-06 Abbott Laboratories Stable compositions for measuring human natriuretic peptides
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
EP1727556A2 (de) * 2004-02-17 2006-12-06 University Of South Florida Material und methoden zur behandlung von entzündlichen erkrankungen und zellproliferationsstörungen
DK2348114T3 (en) 2004-04-21 2018-09-03 Alexion Pharma Inc BONE DELIVERY CONJUGATES AND PROCEDURE TO USE IT FOR TARGETING PROTEINS AGAINST BONE
DE602005026014D1 (de) * 2004-07-15 2011-03-03 Univ Queensland Proteinartige verbindungen und anwendungen davon
AT500800B1 (de) * 2004-09-08 2008-07-15 Biomedica Medizinprodukte Gmbh Verfahren zur bestimmung von probnp
WO2006076471A2 (en) * 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
WO2007022123A2 (en) * 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
EP1853627A2 (de) 2005-02-11 2007-11-14 Amylin Pharmaceuticals, Inc. Gip-analog und hybridpolypeptide mit auswählbaren eigenschaften
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
ES2554713T3 (es) 2005-04-07 2015-12-22 Cardiorentis Ag Uso de un péptido natriurético para tratar insuficiencia cardiaca
US7803901B2 (en) * 2005-09-16 2010-09-28 Mayo Foundation For Medical Education And Research Polypeptides with natriuresis activity
BRPI0709427A2 (pt) * 2006-03-30 2011-07-12 Palatin Technologies Inc "construto cìclico, composição farmacêutica e uso de um composto
US8580746B2 (en) * 2006-03-30 2013-11-12 Palatin Technologies, Inc. Amide linkage cyclic natriuretic peptide constructs
CA2647146A1 (en) * 2006-03-30 2007-10-11 Palatin Technologies, Inc. Linear natriuretic peptide constructs
EP2051585A4 (de) * 2006-04-28 2010-06-02 Univ South Florida Materialien und verfahren zur unterdrückung von entzündungen durch hemmung des vorhof-rezeptors für natriuretische peptide
WO2008021872A1 (en) 2006-08-08 2008-02-21 Mayo Foundation For Medical Education And Research Diuretic and natriuretic polypeptides
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
EP2295445A1 (de) 2006-09-08 2011-03-16 Mayo Foundation for Medical Education and Research Aquaretische und natriuretische Polypeptide ohne Gefäßerweiterungsaktivität
WO2008092019A1 (en) * 2007-01-25 2008-07-31 Mayo Foundation For Medical Education And Research Fgf-23 polypeptides
EP2171053B1 (de) * 2007-07-20 2014-04-23 Mayo Foundation for Medical Education and Research Natriuretische polypeptide
US8357656B2 (en) 2007-09-15 2013-01-22 Mayo Foundation For Medical Education And Research Natriuretic peptide receptor-C agonists
WO2009055644A2 (en) * 2007-10-24 2009-04-30 California Institute Of Technology Methods using the grueneberg ganglion chemosensory system
CL2008003476A1 (es) * 2007-11-21 2009-08-14 Biomarin Pharm Inc Variante del peptido natriuretico de tipo c (cnp); composicion farmaceutica que la comprende; y su uso para tratar una displasia del esqueleto o un trastorno de la musculatura lisa vascular.
WO2009086126A2 (en) * 2007-12-21 2009-07-09 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
US9482677B2 (en) 2008-02-27 2016-11-01 Scios Inc. Method, composition and device for sampling natriuretic peptides in a biological fluid
CA2727085A1 (en) * 2008-06-06 2009-12-10 Mayo Foundation For Medical Education And Research Chimeric natriuretic polypeptides and methods for inhibiting cardiac remodeling
EP2334334A1 (de) * 2008-09-19 2011-06-22 Nektar Therapeutics Polymerkonjugate von nesiritid-peptiden
US20110166063A1 (en) 2008-09-19 2011-07-07 Nektar Therapeutics Polymer conjugates of therapeutic peptides
US8642550B2 (en) * 2008-10-24 2014-02-04 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides without hypotensive inducing capability
US8455438B2 (en) 2008-12-29 2013-06-04 Mayo Foundation For Medical Education And Research Natriuretic polypeptides for reducing or preventing restenosis
US20120053123A1 (en) * 2009-05-05 2012-03-01 Mayo Foundation For Medical Education And Research Natriuretic polypeptides having mutations within their disulfide rings
CA2758581C (en) * 2009-05-20 2022-06-14 Biomarin Pharmaceutical Inc. Variants of c-type natriuretic peptide
US20120108514A1 (en) 2009-07-09 2012-05-03 University Of Iowa Research Foundation Long acting atrial natriuretic peptide (la-anp) and methods for use thereof
CN102470163B (zh) * 2009-07-23 2016-06-15 Igisu株式会社 皮肤外用剂组合物
KR101229546B1 (ko) 2009-08-27 2013-02-05 쿄고 엔도 비염 치료제
WO2012013597A1 (de) 2010-07-28 2012-02-02 Justus-Liebig-Universität Giessen Stoffe und deren verwendung zur beeinflussung natriuretischer peptidrezeptoren
DE102010032482A1 (de) 2010-07-28 2012-02-02 Justus-Liebig-Universität Giessen Stoffe zur Beeinflussung der natriuretischen Peptid-Rezeptoren A und B und deren Verwendung
US8778699B2 (en) 2010-08-04 2014-07-15 Idexx Laboratories, Inc. Detection of degradation products of canine NT-proBNP
US9314507B2 (en) 2010-10-29 2016-04-19 Capricor Therapeutics, Inc. Methods of treatment of heart failure with natriuretic peptides
US9266939B2 (en) 2010-12-27 2016-02-23 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
WO2012099258A1 (ja) 2011-01-21 2012-07-26 株式会社 イギス 脱毛症治療剤
US20120277155A1 (en) 2011-02-25 2012-11-01 Medtronic, Inc. Therapy for kidney disease and/or heart failure
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
EP2715353B1 (de) 2011-05-31 2016-08-24 IDEXX Laboratories, Inc. Nachweis von abbauprodukten von felinem nt-probnp
CN103906761B (zh) 2011-08-30 2016-12-21 梅约医学教育与研究基金会 利钠多肽
EP2750697A4 (de) 2011-09-02 2015-03-25 Medtronic Inc Chimäre natriuretische peptidzusammensetzungen und verfahren zu ihrer herstellung
KR20140084201A (ko) 2011-10-19 2014-07-04 알렉시온 파마 홀딩 알칼리성 포스파타제 및/또는 나트륨이뇨 펩티드를 포함하는 조성물 및 그의 사용 방법
WO2013070741A1 (en) * 2011-11-11 2013-05-16 Mayo Foundation For Medical Education And Research Methods and materials for regulating natriuretic polypeptide function
US9611305B2 (en) 2012-01-06 2017-04-04 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
WO2013151767A1 (en) * 2012-04-02 2013-10-10 Medtronic, Inc. Therapy for kidney disease and/or heart failure by intradermal infusion
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US8835601B2 (en) * 2012-12-21 2014-09-16 Mayo Foundation For Medical Education And Research Natriuretic polypeptide delivery systems
US20140213519A1 (en) * 2013-01-25 2014-07-31 Cardiorentis Ltd. Methods of treating cardiovascular indications
CN103159847B (zh) * 2013-04-12 2014-05-28 叶亮 一种利钠肽及其基因与用途
WO2014209229A1 (en) * 2013-06-25 2014-12-31 National University Of Singapore Vasodilation peptides and uses thereof
US9863900B2 (en) 2014-01-28 2018-01-09 Transtech Systems, Inc. Planar sensor array for non-destructive evaluation of material using electromagnetic impedance
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
US10161893B2 (en) 2014-08-19 2018-12-25 Transtech Systems, Inc. Characterization of material under test (MUT) with electromagnetic impedance spectroscopy
WO2016090251A1 (en) 2014-12-05 2016-06-09 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
CA2973883A1 (en) 2015-01-28 2016-08-04 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
AU2016272282A1 (en) 2015-05-29 2018-01-25 Igisu Co., Ltd. Cyclic peptide, and medicine, external preparation and cosmetic each containing said cyclic peptide
RU2745528C2 (ru) 2015-08-17 2021-03-26 Алексион Фармасьютикалз, Инк. Производство щелочных фосфатаз
US11229686B2 (en) 2015-09-28 2022-01-25 Alexion Pharmaceuticals, Inc. Reduced frequency dosage regimens for tissue non-specific alkaline phosphatase (TNSALP)-enzyme replacement therapy of hypophosphatasia
WO2017074466A1 (en) 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
EP3426286A4 (de) 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung von hypophosphatasie bei kindern
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
CA3019726A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
WO2017214130A1 (en) 2016-06-06 2017-12-14 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
JP7018933B2 (ja) 2016-08-18 2022-02-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド 気管気管支軟化症の治療方法
WO2018034622A1 (en) * 2016-08-18 2018-02-22 National University Of Singapore Peptides with vasodilatory and/or diuretic functions
AU2018243320A1 (en) 2017-03-31 2019-10-10 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (HPP) in adults and adolescents
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862925A (en) * 1973-07-05 1975-01-28 American Home Prod Preparation of somatotropin release inhibiting factor and intermediates therefor
US3842067A (en) * 1973-07-27 1974-10-15 American Home Prod Synthesis of(des-asn5)-srif and intermediates
JPS5726506B2 (de) * 1974-03-08 1982-06-04
US4105602A (en) * 1975-02-10 1978-08-08 Armour Pharmaceutical Company Synthesis of peptides with parathyroid hormone activity
US4161521A (en) * 1975-08-08 1979-07-17 Merck & Co., Inc. Somatostatin analogs
US4051842A (en) * 1975-09-15 1977-10-04 International Medical Corporation Electrode and interfacing pad for electrical physiological systems
DE2626348C3 (de) * 1976-06-11 1980-01-31 Siemens Ag, 1000 Berlin Und 8000 Muenchen Implantierbare Dosiereinrichtung
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
US4383529A (en) * 1980-11-03 1983-05-17 Wescor, Inc. Iontophoretic electrode device, method and gel insert
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4757048A (en) * 1985-11-05 1988-07-12 Biotechnology Research Associates J.V. Synthetic analogs of atrial natriuretic peptides
US5560922A (en) * 1986-05-30 1996-10-01 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit using a polyacrylate adhesive polymer and process
US4804650A (en) * 1986-10-28 1989-02-14 Biotechnology Research Associates, J.V. Analogs of atrial natriuretic peptides
US5691310A (en) * 1987-09-29 1997-11-25 Vesely; David L. Methods of treatment using proANF peptides
US4935492A (en) * 1987-12-24 1990-06-19 California Biotechnology Inc. Cyclic analogs of atrial natriuretic peptides
US5047397A (en) * 1988-08-26 1991-09-10 California Biotechnology Inc. Linear analogs of atrial natriuretic peptides
CA1339210C (en) 1988-05-31 1997-08-05 John Lewicki Recombinant techniques for production of novel natriuretic and vasodilator peptides
US5114923A (en) 1988-05-31 1992-05-19 California Biotechnology Inc. Recombinant techniques for production of novel natriuretic and vasodilator peptides
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5202239A (en) 1990-08-07 1993-04-13 Scios Nova Inc. Expression of recombinant polypeptides with improved purification
EP0659209A1 (de) 1991-07-26 1995-06-28 The University Of Rochester Krebstherapie unter verwendung maligner zellen
AU6360394A (en) 1993-03-03 1994-09-26 Mayo Foundation For Medical Education And Research Vasonatrin peptide and analogs thereof
PT914344E (pt) 1996-03-04 2005-10-31 Scios Inc Ensaio e reagentes para a quantificacao de hbnp
US5848956A (en) * 1997-03-18 1998-12-15 Grettner; Norman L. Multi-purpose lat sling
AU9487698A (en) * 1997-09-11 1999-03-29 Music Foundation For Research Development Methods and compositions for treating cardiac and renal disorders with atrial natriuretic peptide and tissue kallikrein gene therapy
AU5043900A (en) * 1999-05-24 2000-12-12 Mayo Foundation For Medical Education And Research Adenovirus vectors encoding brain natriuretic peptide
US6407211B1 (en) * 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides

Also Published As

Publication number Publication date
DK1242452T3 (da) 2007-06-11
US7964564B2 (en) 2011-06-21
US6818619B2 (en) 2004-11-16
US20020082219A1 (en) 2002-06-27
ATE353916T1 (de) 2007-03-15
US20090170756A1 (en) 2009-07-02
JP2003517005A (ja) 2003-05-20
ES2282160T3 (es) 2007-10-16
US7384917B2 (en) 2008-06-10
CA2395585C (en) 2014-09-09
US20030069186A1 (en) 2003-04-10
CA2395585A1 (en) 2001-06-21
AU2433901A (en) 2001-06-25
US20050059600A1 (en) 2005-03-17
US6407211B1 (en) 2002-06-18
EP1242452A2 (de) 2002-09-25
EP1242452B1 (de) 2007-02-14
PT1242452E (pt) 2007-05-31
WO2001044284A3 (en) 2002-01-31
JP5031964B2 (ja) 2012-09-26
WO2001044284A2 (en) 2001-06-21
DE60033431T2 (de) 2007-11-29

Similar Documents

Publication Publication Date Title
DE60033431D1 (de) Chimärische natriuretische peptide
GEP20105118B (en) Anti-vegf antibodies
MXPA03007319A (es) Anticuerpos contra egfr modificados, con inmunogenicidad reducida.
DE69534778D1 (en) Cathepsin-02-protease
WO2001053455A3 (en) Novel nucleic acids and polypeptides
WO2001075067A3 (en) Novel nucleic acids and polypeptides
WO2001057188A3 (en) Novel nucleic acids and polypeptides
WO2001057190A3 (en) Novel nucleic acids and polypeptides
WO2002022660A3 (en) Novel nucleic acids and polypeptides
WO2001066689A3 (en) Novel nucleic acids and polypeptides
WO2002031111A3 (en) Novel nucleic acids and polypeptides
WO2001088088A3 (en) Novel nucleic acids and polypeptides
ZA200110161B (en) Anti-avB3 recombinant human antibodies, nucleic acids encoding same and methods of use.
WO2002059260A3 (en) Nucleic acids and polypeptides
EP1162264A3 (de) Chimärer Hormonrezeptor
ATE368688T1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
WO2004087874A3 (en) Novel nucleic acids and polypeptides
ITRM990803A0 (it) Peptidi stabilizzanti, polipeptidi ed anticorpi che li comprendono.
WO2002018424A3 (en) Nucleic acids and polypeptides
BR9916507A (pt) Proteìnas
WO2001079449A3 (en) Novel nucleic acids and polypeptides
DE69938130D1 (de) Neue peptide
BR0008187A (pt) Controle biológico de nematódeos
EA200400392A1 (ru) Связывающий каспазу-8 белок, его получение и применение
PE20399A1 (es) Muteina ob

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: BURNETT, JOHN JR., ROCHESTER, MN, US

Inventor name: LISY, ONDREJ, ROCHESTER, MN, US

8364 No opposition during term of opposition